150 related articles for article (PubMed ID: 37907756)
1. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
Yang L; Lai X; Yang T; Lu Y; Liu L; Shi J; Zhao Y; Wu Y; Chen Y; Yu J; Xiao H; Ouyang G; Ren J; Cao J; Hu Y; Tan Y; Ye Y; Cai Z; Xu W; Huang H; Luo Y
Bone Marrow Transplant; 2024 Jan; 59(1):85-92. PubMed ID: 37907756
[TBL] [Abstract][Full Text] [Related]
2. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
4. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
5. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
[No Abstract] [Full Text] [Related]
6. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
Schmid C; Labopin M; Schaap N; Veelken H; Brecht A; Stadler M; Finke J; Baron F; Collin M; Bug G; Ljungman P; Blaise D; Tischer J; Bloor A; Kulagin A; Giebel S; Gorin NC; Esteve J; Ciceri F; Savani B; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Feb; 57(2):215-223. PubMed ID: 34750562
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
8. Donor Lymphocyte Infusion for Relapsed Acute Leukemia or Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation: A Single-Institute Retrospective Analysis.
Ogasawara M; Nozu R; Miki K; Sugimura S; Kojima K; Hidaka D; Ogasawara R; Okada K; Sugita J; Kobayashi N; Imamura M; Ota S
Intern Med; 2024 Jan; 63(2):197-205. PubMed ID: 37225485
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.
Yan CH; Wang Y; Wang JZ; Chen YH; Chen Y; Wang FR; Sun YQ; Mo XD; Han W; Chen H; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2016 Sep; 9(1):87. PubMed ID: 27629395
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis.
Yang L; Tan Y; Shi J; Zhao Y; Yu J; Hu Y; Lai X; Yang Y; Huang H; Luo Y
Bone Marrow Transplant; 2021 Mar; 56(3):664-672. PubMed ID: 33077902
[TBL] [Abstract][Full Text] [Related]
15. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
[TBL] [Abstract][Full Text] [Related]
16. Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients.
van der Zouwen B; Koster EAS; von dem Borne PA; Oosten LEM; Roza-Scholten MWI; Snijders TJF; van Lammeren D; van Balen P; Marijt WAF; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Ann Hematol; 2023 May; 102(5):1203-1213. PubMed ID: 36881136
[TBL] [Abstract][Full Text] [Related]
17. Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant.
Hou MH; Lee CY; Ho CY; Yu TY; Hung GY; Huang FL; Chiou TJ; Liu CY; Yen HJ
J Chin Med Assoc; 2023 Nov; 86(11):991-1000. PubMed ID: 37697465
[TBL] [Abstract][Full Text] [Related]
18. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
20. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
[No Abstract] [Full Text] [Related]
[Next] [New Search]